Earle Burgess: Bipolar androgen therapy for advanced prostate cancer
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared on LinkedIn:
“Bipolar androgen therapy (BAT) for advanced prostate cancer: I am an advocate in the appropriate patient setting based on the TRANSFORMER study.
TRANSFORMER results and protocol.
Unfortunately we don’t know in advance which patients are most likely to benefit from using BAT.
Data presented from the TRANSFORMER study at ASCO24 suggest patients whose tumors contain an androgen receptor (AR) gene alteration may be the group most likely to benefit from BAT.
‘TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer‘ | Journal of Clinical Oncology
Authors: ”
Source: Earle Burgess/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023